SEE2CURE
Develops a fluorescent tracer to help surgeons detect microscopic abdominal metastases during cancer surgery
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-09
About SEE2CURE
See2cure is developing a fluorescent imaging agent that targets a cancer biomarker and makes microscopic abdominal metastases visible in real time during surgery. It is designed for use with imaging systems already available in operating rooms.
The first intended indication is advanced ovarian cancer, with potential applications in digestive cancers. The company is based in Toulouse, France, and was founded in 2024. Its development plan includes a regulatory preclinical phase followed by first-in-human trials.
Product: A fluorescent tracer for real-time imaging of microscopic metastases during oncological surgery.
Jobs at SEE2CURE
More biotech & pharma companies
Sensorion
Biotechnology company developing therapies for people with hearing loss and inner ear disordersNew on EvolcSeqens
Manufactures pharmaceutical and specialty chemical ingredients for industrial customersNew on EvolcSerb
Develops and manufactures critical-care and rare-disease medicines for healthcare professionals and health systems worldwideNew on EvolcSerendip Innovations
Plant-produced RNA delivery vectors for pharmaceutical companies developing targeted RNA therapiesYoung companyNew on EvolcSfri
Manufacturer of in vitro diagnostic instruments and reagents for laboratories and medical professionals worldwideNew on EvolcSmartlife Biosciences
Sequencing, oligonucleotide synthesis and bioinformatics services for research laboratories and scientistsYoung companyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
No confirmed website technologies in the latest recorded checks.
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.